Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed newly diagnosed clear cell renal cell carcinoma, meeting 1 of the following criteria:~  * Localized disease, as evidenced by intact, bulky, and primary renal lesions (T1 \> 3 cm, any T2, T3, or T4) appropriate for nephrectomy~ * Limited metastatic disease, as evidenced by any renal primary (T1 \> 3 cm, any T2, T3, or T4) appropriate for cytoreductive nephrectomy~ * Isolated abdominal/pelvic recurrence with limited metastatic burden (minimum size \> 2 cm) appropriate for metastasectomy~* No known brain metastasis~  * Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude brain metastasis~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group performance status 0-1~* Hemoglobin ≥ 9.0 g/dL~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Total bilirubin ≤ 1.5 times upper limit of normal (ULN)~* Alanine aminotransferase and Aspartate aminotransferase ≤ 2.5 times ULN (≤ 5 times ULN with liver involvement)~* Creatinine ≤ 1.5 times ULN~* Estimated glomerular filtration rate \> 30 mL/min (for patients receiving Gd-enhanced MRI)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception prior to, during (men and women), and for at least 3 months after (men) completion of study therapy~* Adequate cardiac and pulmonary status for operative therapy~* No active clinically serious infection \> CTCAE grade 2~* No known HIV, hepatitis B, or hepatitis C infections~* No serious non-healing wound, ulcer, or bone fracture~* No significant traumatic injury within the past 4 weeks~* No pulmonary hemorrhage/bleeding event ≥ CTCAE grade 2 within the past 4 weeks~* No other hemorrhage/bleeding event ≥ CTCAE grade 3 within the past 4 weeks~* No history of an uncontrolled bleeding disorder including, but not limited to, any of the following:~  * Bleeding diathesis~ * Coagulopathy~* No cardiac disease or condition including, but not limited to, any of the following:~  * New York Heart Association class II-IV congestive heart failure~ * Unstable angina (anginal symptoms at rest)~ * New onset angina beginning within the last 3 months~ * Myocardial infarction within the past 6 months~ * Cardiac ventricular arrhythmias requiring antiarrhythmic therapy~* No uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 100 mm Hg) despite optimal medical management~* No thrombolic or embolic events within the past 6 months (e.g., cerebrovascular accident including transient ischemic attacks)~* No condition that impairs the ability to swallow whole pills~* No malabsorption problem~* No contraindication to MRI, including, but not limited to, any of the following:~  * Ferromagnetic implants~ * Dental work~ * Pacemakers~ * Metallic implants~ * Severe claustrophobia which precludes closed MRI testing~* No known or suspected allergy to sorafenib tosylate~* No contraindication or allergy to gadolinium (e.g., end stage renal disease requiring hemodialysis)~* No intercurrent illness or situation which, in the judgment of the investigator, would affect assessments of clinical status and study endpoints significantly~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 weeks since prior major surgery or open biopsy~* No prior therapy with tyrosine kinase or vascular endothelial growth factor inhibitors (e.g., sunitinib malate, sorafenib, or bevacizumab)~* No concurrent Hypericum perforatum (St. John's wort) or rifampin~* No concurrent use of illicit drugs or other substances that may, in the opinion of the investigator, have a reasonable chance of contributing to toxicity or interfering with study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sorafenib (Type: EXPERIMENTAL): Eligible patients undergo pre-treatment DW-MRI of the abdomen and pelvis. Patient then receive Sorafenib 400mg orally twice daily on days 1-28. Following completion of 28 days of sorafenib, patients obtain a second DW-MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).